Document Detail


High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients.
MedLine Citation:
PMID:  23208590     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Stearoyl-CoA desaturase 1 (SCD1) is an essential regulator of fatty acid synthesis. We have previously shown that overexpression of SCD1 increases the growth of breast cancer cell lines. The purpose of this study was to determine the relationship between SCD1 expression level and clinical-pathologic characteristics and survival of patients with breast cancer. Fine-needle aspirates were collected from the primary tumors of 250 patients with stage I-III breast cancer. Demographic and clinical characteristics including patient age, ethnicity, and menopausal status and tumor clinical stage, grade, and subtype were reviewed. SCD1 expression was analyzed using reverse-phase protein arrays. Samples were divided into high or low SCD1 expression levels based on a cut-off determined from martingale residual plots and regression tree analysis. SCD1 levels were significantly higher in tumors from patients >50-years old compared to patients ≤50-years old and were lower in triple-negative (estrogen/progesterone receptor-negative and human epidermal growth factor receptor-2-negative) breast cancers than other tumor subtypes. After adjusting for patient age, tumor subtype, tumor grade, and clinical stage, we found that patients with primary breast cancers expressing high SCD1 levels had significantly shorter relapse-free survival (RFS) (P = 0.0140) and overall survival (OS) (P = 0.039) in multivariable analysis. We conclude that SCD1 expression varies by breast cancer subtype and that high levels of SCD1 expression are associated with significantly shorter RFS and OS in multivariable analysis. Future studies are needed to define the role of SCD1 in the malignant phenotype of breast cancer and to evaluate the potential for SCD1 as a therapeutic target.
Authors:
Ashley M Holder; Ana M Gonzalez-Angulo; Huiqin Chen; Argun Akcakanat; Kim-Anh Do; W Fraser Symmans; Lajos Pusztai; Gabriel N Hortobagyi; Gordon B Mills; Funda Meric-Bernstam
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-12-04
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  137     ISSN:  1573-7217     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-24     Completed Date:  2013-05-27     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  319-27     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Breast Neoplasms / enzymology*,  mortality
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Multivariate Analysis
Protein Array Analysis
Receptor, erbB-2 / metabolism
Receptors, Estrogen / metabolism
Receptors, Progesterone / metabolism
Stearoyl-CoA Desaturase / metabolism*
Grant Support
ID/Acronym/Agency:
1K23CA121994-01/CA/NCI NIH HHS; 3UL1RR024148/RR/NCRR NIH HHS; K23 CA121994/CA/NCI NIH HHS; P30 CA016672/CA/NCI NIH HHS; P30 CA016672/CA/NCI NIH HHS; T32 CA009599/CA/NCI NIH HHS; T32 CA009599-23/CA/NCI NIH HHS; UL1 RR024148/RR/NCRR NIH HHS; UL1TR000371/TR/NCATS NIH HHS
Chemical
Reg. No./Substance:
0/Receptors, Estrogen; 0/Receptors, Progesterone; EC 1.14.19.1/SCD1 protein, human; EC 1.14.19.1/Stearoyl-CoA Desaturase; EC 2.7.10.1/ERBB2 protein, human; EC 2.7.10.1/Receptor, erbB-2
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lack of expression of the proteins GMPR2 and PPAR? are associated with the basal phenotype and patie...
Next Document:  Systems for the provision of oral health care in the black sea countries. Part 12: Ukraine.